Health and Healthcare

Gilead Tops Estimates in 2Q

gilead
courtesy of Gilead Sciences
Gilead Sciences Inc. (NASDAQ: GILD) reported second-quarter financial results Tuesday after the markets closed. The biotech giant had $3.15 in earnings per share (EPS) on $8.2 billion in revenue compared to Thomson Reuters consensus estimates of $2.71 in EPS on $7.61 billion in revenue. The second quarter from the previous year had $2.36 in EPS and $6.53 billion in revenue.

The company updated its guidance for the full year; it increased net product sales to a range of $28 billion to $29 billion. There are consensus estimates of $10.87 in EPS on $30.36 billion in revenue.

During the quarter, Gilead signed a definitive agreement to acquire EpiTherapeutics, a privately-held Danish company. EpiTherapeutics generated a library of first-in-class, selective small molecule inhibitors of epigenetic regulation of gene transcription, in particular histone demethylases.

The board of directors declared a cash dividend of $0.43 per share of common stock for the third quarter. The dividend is payable on September 29, to stockholders of record at the close of business on September 16.

In terms of its products, Gilead reported sales for the quarter:

  • Harvoni sold $3.61 billion.
  • Sovaldi sold $1.29 billion.
  • Truvada sold $849 million.
  • Atripla sold $782 million.
  • Stribild sold $447 million.
  • Complera/Eviplera sold $367 million.
  • Viread sold $271 million.

At the end of this quarter Gilead had $14.7 billion of cash, cash equivalents and marketable securities compared to $14.5 billion at the end of the first quarter. During the second quarter of 2015, Gilead generated $5.7 billion in operating cash flow, utilized $900 million to repurchase 9 million shares under the $15.0 billion share repurchase plan approved in January 2015 and $3.9 billion to retire 46 million warrants related to the 2016 convertible debt.

Shares of Gilead closed Tuesday up 2.3% at $113.07. Following the release of the earnings report, shares were up 2.6% at $116.00. The stock has a consensus analyst price target of $124.47 and a 52-week trading range of $85.95 to $123.37.

ALSO READ: 7 Bizarre Medical Treatments Back in Use

100 Million Americans Are Missing This Crucial Retirement Tool

The thought of burdening your family with a financial disaster is most Americans’ nightmare. However, recent studies show that over 100 million Americans still don’t have proper life insurance in the event they pass away.

Life insurance can bring peace of mind – ensuring your loved ones are safeguarded against unforeseen expenses and debts. With premiums often lower than expected and a variety of plans tailored to different life stages and health conditions, securing a policy is more accessible than ever.

A quick, no-obligation quote can provide valuable insight into what’s available and what might best suit your family’s needs. Life insurance is a simple step you can take today to help secure peace of mind for your loved ones tomorrow.

Click here to learn how to get a quote in just a few minutes.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.